SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
SELLAS Life Sciences' pivotal Phase 3 REGAL trial of galinpepimut-S in acute myeloid leukemia reached the pre-specified 80th event, triggering the final analysis of the study. The company will proceed with database lock and unblinding, and expects to report preliminary topline overall survival results this quarter under the pre-specified statistical analysis plan.
Key figures
- Drug Name
- galinpepimut-S (GPS)
- Phase Of Trial
- Phase 3
- Nct number
- NCT04229979
- Trial name
- REGAL
- Events reached
- 80
- Primary endpoint
- overall survival
- Patient population
- AML patients in second complete remission (CR2)
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.